MAJOR RECOMMENDATIONS The USPSTF recommends against PSA-based screening for prostate cancer due to moderate or high certainty that the test has no net benefit or the harms outweigh the benefits (grade D). The AUA recommends shared decision making for men aged 55 to 69 years; for men electing to be screened, an interval of 2 years or more may be preferable to annual screening. The AUA recommends against PSA screening in men younger than 40 years, against routine screening between ages 40 and 54 years for men at average risk, and against routine screening in men older than 70 years or any man with less than a 10- to 15-year life expectancy.